文献速递临床试验与 GCP流行病学与生物统计基础与转化研究

针对分子靶向药物的贝叶斯自适应标志物分层设计及定制分层模型

A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling.
PubMed 文献 · Stat Med · 2019-04-09

针对分子靶向药物(MTA)疗效随生物标志物不同而变化的问题,提出一种贝叶斯分层模型,利用标志物信息在标准治疗组不同亚组间借用信息,并通过定制方程确定先验信息量。基于该模型开发贝叶斯自适应设计,指导治疗分配并检验亚组疗效及预测标志物效应。模拟研究和真实试验应用显示该设计具有理想操作特性且优于现有设计。

要点

  • 传统标志物分层设计(MSD)采用β-二项模型,忽略标志物仅对MTA有预测性、标准治疗反应率在各亚组近似一致的事实。
  • 提出的贝叶斯分层模型通过分层先验在标准治疗组亚组间借用信息,提高设计效率。
  • 基于该模型的自适应设计可指导治疗分配并检验亚组疗效及预测标志物效应,模拟和真实试验中优于现有设计。

核心结论

  • 模拟研究和真实试验应用表明,所提出的设计具有理想的操作特性,并优于现有设计。

研究设计与样本

  • 提出一种贝叶斯分层模型,将生物标志物信息纳入考虑,使用分层先验在标准治疗组不同亚组间借用信息。
  • 先验信息量通过求解反映医生专业意见的「定制」方程确定。
  • 基于该分层模型开发贝叶斯自适应设计,指导治疗分配并检验亚组疗效及预测标志物效应。

主要发现

  • 传统β-二项模型忽略标志物一般仅对MTA有预测性,而标准治疗反应率在标志物分层各亚组间近似一致。
  • 所提出的分层模型利用分层先验在标准治疗组亚组间借用信息,提高设计效率。
  • 模拟研究和真实试验应用显示,所提出的设计具有理想操作特性,且优于现有设计。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

It is well known that the treatment effect of a molecularly targeted agent (MTA) may vary dramatically, depending on each patient's biomarker profile. Therefore, for a clinical trial evaluating MTA, it is more reasonable to evaluate its treatment effect within different marker subgroups rather than evaluating the average treatment effect for the overall population. The marker-stratified design (MSD) provides a useful tool to evaluate the subgroup treatment effects of MTAs. Under the Bayesian framework, the beta-binomial model is conventionally used under the MSD to estimate the response rate and test the hypothesis. However, this conventional model ignores the fact that the biomarker used in the MSD is, in general, predictive only for the MTA. The response rates for the standard treatment can be approximately consistent across different subgroups stratified by the biomarker. In this paper, we proposed a Bayesian hierarchical model incorporating this biomarker information into consideration. The proposed model uses a hierarchical prior to borrow strength across different subgroups of patients receiving the standard treatment and, therefore, improve the efficiency of the design. Prior informativeness is determined by solving a "customized" equation reflecting the physician's professional opinion. We developed a Bayesian adaptive design based on the proposed hierarchical model to guide the treatment allocation and test the subgroup treatment effect as well as the predictive marker effect. Simulation studies and a real trial application demonstrate that the proposed design yields desirable operating characteristics and outperforms the existing designs.

来源:Stat Med,查看原文。版权归原作者所有。

引用

  1. Zang Y, Guo B, Han Y, et al. A Bayesian adaptive marker-stratified design for molecularly targeted agents with customized hierarchical modeling. Stat Med. 2019. PMID: 30968435. doi:10.1002/sim.8159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。